Structure Therapeutics Inc. American Depositary Shares (GPCR)vsRegeneron Pharmaceuticals Inc (REGN)
GPCR
Structure Therapeutics Inc. American Depositary Shares
$39.10
-0.13%
HEALTHCARE · Cap: $2.78B
REGN
Regeneron Pharmaceuticals Inc
$714.89
+0.82%
HEALTHCARE · Cap: $74.34B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
GPCR
Avoid30
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GPCR.
Margin of Safety
+51.3%
Fair Value
$1456.29
Current Price
$714.89
$741.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.7%
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : GPCR
The strongest argument for GPCR centers on Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Altman Z-Score, Market Cap, Profit Margin. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : GPCR
The primary concerns for GPCR are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
GPCR profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.30 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 30/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Structure Therapeutics Inc. American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?